Phase II trial of motexafin gadolinium (MGd, xcytrin®) and cranial radiation in newly diagnosed glioblastoma multiforme (GBM) Article

Suh, J, Mehta, M, Chang, E et al. (2002). Phase II trial of motexafin gadolinium (MGd, xcytrin®) and cranial radiation in newly diagnosed glioblastoma multiforme (GBM) . INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 54(2), 246. 10.1016/s0360-3016(02)03485-5

cited authors

  • Suh, J; Mehta, M; Chang, E; Timmerman, R; Yamada, J; Gaspar, L; Leibenhaut, M; Rao, A; Yung, W; Phan, S

authors

publication date

  • October 1, 2002

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • Brain Cancer
  • Brain Disorders
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Neurosciences
  • Radiation Oncology
  • Rare Diseases

Digital Object Identifier (DOI)

publisher

  • Elsevier

start page

  • 246

volume

  • 54

issue

  • 2